Epidermal growth factor receptor in CRC patients in the Era of the RAS

Basit Öğe Kaydı
dc.contributor.authorYanmaz, Mustafa Teoman
dc.contributor.authorDemir, Gökhan
dc.contributor.authorErdamar, Sibel
dc.contributor.authorKeskin, Serkan
dc.contributor.authorAydın, Muhammet Fatih
dc.contributor.authorGüner, Şebnem İzmir
dc.date.accessioned2021-05-15T12:40:37Z
dc.date.available2021-05-15T12:40:37Z
dc.date.issued2015
dc.departmentTıp Fakültesi, Onkoloji Anabilim Dalıen_US
dc.description.abstractThe aim of this study was to investigate EGFR expression patterns and the effect of EGFR expression on stage, prognosis and response to conventional chemotherapy agents other than monoclonal antibodies in CRC patients. This study included 59 metastatic CRC patients. The expression of EGFR was quantified by immunochemistry in biopsy specimens that were obtained before treatment was initiated. The cases were considered to be positive for EGFR if >1% of the tumor cells had complete circumferential membranous staining. The median age of the patients was 54.6 years, and 59% of the patients were male. Twenty-six patients presented with stage IV disease, and the remaining patients developed distant metastasis during follow-up. Fifty-one patients were treated with regimens containing irinotecan. The numbers of patients with EGFR expression in the primary tumors, the metastatic lymph nodes and the normal colonic tissue were 34 (65.4%), 10 (76.9%) and 34 (65.4%) respectively The initial disease stage and lymph node stage were correlated with EGFR expression (p<0.05). Additionally, EGFR positivity was correlated with a statistically significant reduction in the response rate to chemotherapy, the overall survival (21 vs. 28 months) and the progression-free survival (15 vs. 22 months) in metastatic patiens treated with chemotherapy other than targeted therapies. In conclusion, EGFR expression in correlated with stage in all CRC patients and response to chemotherapy and survival in metastatic CRC patients.en_US
dc.identifier.doi10.5754/hge14874
dc.identifier.endpage44en_US
dc.identifier.issn0172-6390
dc.identifier.issue137en_US
dc.identifier.pmid25911864
dc.identifier.scopus2-s2.0-84928568713
dc.identifier.scopusqualityN/A
dc.identifier.startpage40en_US
dc.identifier.urihttps://doi.org/10.5754/hge14874
dc.identifier.urihttps://hdl.handle.net/20.500.12939/635
dc.identifier.volume62en_US
dc.identifier.wosWOS:000352115700008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYanmaz, Mustafa Teoman
dc.language.isoen
dc.publisherH G E Update Medical Publishing S Aen_US
dc.relation.ispartofHepato-Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEGFRen_US
dc.subjectColorectal Canceren_US
dc.subjectOutcomeen_US
dc.titleEpidermal growth factor receptor in CRC patients in the Era of the RAS
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu